Jin Medical Price to Free Cash Flow Ratio 2023-2024 | ZJYL

Jin Medical price to free cash flow ratio from 2023 to 2024. Price to free cash flow ratio can be defined as

Jin Medical Price to Free Cash Flow Ratio 2023-2024 | ZJYL

Jin Medical price to free cash flow ratio from 2023 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$231B
Boston Scientific (BSX)$155.5B
Stryker (SYK)$147.4B
EssilorLuxottica (ESLOY)$140.8B
Medtronic (MDT)$112.8B
Lonza Group Ag (LZAGY)$47.1B
Haleon (HLN)$44.8B
GE HealthCare Technologies (GEHC)$42.1B
Agilent Technologies (A)$39B
ResMed (RMD)$34.2B
Terumo (TRUMY)$26.3B
Koninklijke Philips (PHG)$23.5B
Zimmer Biomet Holdings (ZBH)$20.6B
Insulet (PODD)$20.2B
Baxter (BAX)$17.1B
Sunny Optical Technology (SNPTF)$11.3B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$9.5B
Bio-Rad Laboratories (BIO)$8B
Demant (WILYY)$7.9B
Lantheus Holdings (LNTH)$5.6B
Prestige Consumer Healthcare (PBH)$4.2B
ICU Medical (ICUI)$4B
Envista Holdings (NVST)$3.7B
Perrigo (PRGO)$3.4B
Haemonetics (HAE)$3.2B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.8B
LeMaitre Vascular (LMAT)$2.3B